| review article | Q7318358 |
| scholarly article | Q13442814 |
| P2093 | author name string | Zhihua Ruan | |
| Lin Cheng | |||
| P2860 | cites work | TIM-1 and TIM-4 glycoproteins bind phosphatidylserine and mediate uptake of apoptotic cells. | Q24657708 |
| The blockade of immune checkpoints in cancer immunotherapy | Q27860852 | ||
| CEACAM1 regulates TIM-3-mediated tolerance and exhaustion | Q28115443 | ||
| Tumor-infiltrating DCs suppress nucleic acid-mediated innate immune responses through interactions between the receptor TIM-3 and the alarmin HMGB1 | Q28116224 | ||
| Identification of Tapr (an airway hyperreactivity regulatory locus) and the linked Tim gene family | Q28207890 | ||
| T and B cell hyperactivity and autoimmunity associated with niche-specific defects in apoptotic body clearance in TIM-4-deficient mice | Q30494990 | ||
| Identification of Tim4 as a phosphatidylserine receptor | Q33303850 | ||
| Reversal of NK-cell exhaustion in advanced melanoma by Tim-3 blockade | Q33714165 | ||
| RepSox slows decay of CD34+ acute myeloid leukemia cells and decreases T cell immunoglobulin mucin-3 expression | Q33816240 | ||
| Autophagy inhibition enhances vorinostat-induced apoptosis via ubiquitinated protein accumulation | Q33937865 | ||
| Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity | Q34161493 | ||
| Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen–specific CD8+ T cell dysfunction in melanoma patients | Q34161579 | ||
| Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape | Q34241893 | ||
| Tim-3 expression in cervical cancer promotes tumor metastasis | Q34555771 | ||
| Decreased galectin-9 and increased Tim-3 expression are related to poor prognosis in gastric cancer | Q35067641 | ||
| CD8(+) T cells specific for tumor antigens can be rendered dysfunctional by the tumor microenvironment through upregulation of the inhibitory receptors BTLA and PD-1. | Q35783166 | ||
| Tim-3 is an inducible human natural killer cell receptor that enhances interferon gamma production in response to galectin-9 | Q35876978 | ||
| Tim-3 marks human natural killer cell maturation and suppresses cell-mediated cytotoxicity | Q35909663 | ||
| Upregulation of TIM-3 and PD-1 on CD4+ and CD8+ T Cells Associated with Dysfunction of Cell-Mediated Immunity after Colorectal Cancer Operation | Q37055901 | ||
| Combined TIM-3 blockade and CD137 activation affords the long-term protection in a murine model of ovarian cancer | Q37368087 | ||
| TIM genes: a family of cell surface phosphatidylserine receptors that regulate innate and adaptive immunity | Q37763998 | ||
| Autophagy as a target for anticancer therapy | Q37876679 | ||
| Tim-3, a negative regulator of anti-tumor immunity | Q37973887 | ||
| TIM-3 as a therapeutic target for malignant stem cells in acute myelogenous leukemia | Q38035447 | ||
| The T-cell immunoglobulin and mucin domain (Tim) gene family in asthma, allergy, and autoimmunity | Q38081296 | ||
| TIM-3 as a novel therapeutic target for eradicating acute myelogenous leukemia stem cells | Q38138901 | ||
| PD-1 and Tim-3 regulate the expansion of tumor antigen-specific CD8⁺ T cells induced by melanoma vaccines | Q38264346 | ||
| Tim-3 fosters HCC development by enhancing TGF-β-mediated alternative activation of macrophages. | Q38917897 | ||
| Blocked autophagy sensitizes resistant carcinoma cells to radiation therapy | Q40006232 | ||
| Macroautophagy inhibition sensitizes tamoxifen-resistant breast cancer cells and enhances mitochondrial depolarization | Q40028670 | ||
| Tumor-induced senescent T cells promote the secretion of pro-inflammatory cytokines and angiogenic factors by human monocytes/macrophages through a mechanism that involves Tim-3 and CD40L. | Q41904511 | ||
| Tim-3 expression in tumour-associated macrophages: a new player in HCC progression | Q42161787 | ||
| The expression of Tim-3 in peripheral blood of ovarian cancer | Q42272038 | ||
| Genetic variations of PD1 and TIM3 are differentially and interactively associated with the development of cirrhosis and HCC in patients with chronic HBV infection | Q42280004 | ||
| Prognostic value of T cell immunoglobulin mucin-3 in prostate cancer | Q42281463 | ||
| Tumor immunity times out: TIM-3 and HMGB1. | Q43141630 | ||
| Ectopic expression of TIM-3 in lung cancers: a potential independent prognostic factor for patients with NSCLC. | Q43529147 | ||
| TIM-4 glycoprotein-mediated degradation of dying tumor cells by autophagy leads to reduced antigen presentation and increased immune tolerance | Q44110792 | ||
| T-cell immunoglobulin- and mucin-domain-containing molecule 3 gene polymorphisms and prognosis of non-small-cell lung cancer | Q44642609 | ||
| TIM-3 is a promising target to selectively kill acute myeloid leukemia stem cells | Q45077632 | ||
| Tim-3/galectin-9 signaling pathway mediates T-cell dysfunction and predicts poor prognosis in patients with hepatitis B virus-associated hepatocellular carcinoma. | Q45358316 | ||
| Combined blockade of TIM-3 and TIM-4 augments cancer vaccine efficacy against established melanomas. | Q45988106 | ||
| T cell immunoglobulin- and mucin-domain-containing molecule 3 gene polymorphisms and susceptibility to pancreatic cancer. | Q54303561 | ||
| T-cell immunoglobulin- and mucin-domain-containing molecule 3 gene polymorphisms and renal cell carcinoma | Q83799126 | ||
| Genetic variations and haplotypes in TIM-3 gene and the risk of gastric cancer | Q84974532 | ||
| P433 | issue | 10 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 2458-62 | |
| P577 | publication date | 2015-01-01 | |
| P1433 | published in | Human Vaccines & Immunotherapeutics | Q21072749 |
| P1476 | title | Tim-3 and Tim-4 as the potential targets for antitumor therapy | |
| P478 | volume | 11 |
| Q48614611 | Concordant bone marrow involvement of diffuse large B-cell lymphoma represents a distinct clinical and biological entity in the era of immunotherapy. |
| Q92783939 | Development of a protein-based system for transient epigenetic repression of immune checkpoint molecule and enhancement of antitumour activity of natural killer cells |
| Q41672129 | Effects of Tim-3 silencing on the viability of fibroblast-like synoviocytes and lipopolysaccharide-induced inflammatory reactions |
| Q26769884 | Novel cancer antigens for personalized immunotherapies: latest evidence and clinical potential |
| Q89685712 | T lymphocyte-targeted immune checkpoint modulation in glioma |
| Q58558279 | TIM-3, a promising target for cancer immunotherapy |
| Q90725991 | TLR-3 Stimulation Skews M2 Macrophages to M1 Through IFN-αβ Signaling and Restricts Tumor Progression |
| Q50119256 | The Potential Role of Inhibitory Receptors in the Treatment of Psoriasis |
| Q38699771 | The significance of TIMD4 expression in clear cell renal cell carcinoma |
| Q40137306 | Tim-3 as a diagnostic and prognostic biomarker of osteosarcoma |
| Q92001030 | Tim-4 in Health and Disease: Friend or Foe? |
| Q50698174 | [Effect of inhibiting TIM-4 function in Kupffer cells on liver graft rejection in mice]. |
Search more.